Leadership Team

Brent Zettl, President and CEO

Mr. Zettl, BScA Distinction (Agriculture), is a pioneer of the Canadian medical cannabis industry. He co-founded Prairie Plant Systems Inc. and CanniMed Therapeutics Inc. in 1988. CanniMed was the exclusive supplier of medical cannabis to Health Canada from 2000 to 2014. In March 2018, CanniMed was acquired by Aurora Cannabis Inc. for ~CAD$1.2 billion, the largest acquisition of a cannabis company at the time.

Keith Carpenter, Chief Strategy and Investment Officer

Mr. Carpenter, BA (Economics), MBA, CFA, has more than 20 years of investment experience, spanning both the buy and sell-side. He has spent the last ten in agriculture equity research, where he was a Brendan Wood Top Gun-ranked analyst and StarMine Award recipient.

Rob Harding , Chief Financial Officer

Mr. Harding, MBA, CPA, CMA, has more than 20 years of experience building dynamic, high-performing finance teams and successfully leading companies through public and private financing. He was the CFO at Athabasca Oil, achieving a peak market valuation of $7 billion. His most recent position was CFO of Radicle, where he was involved in the development of Canada’s largest independent green fund.

Dr. Lionel Marks de Chabris, Chief Medical Officer

Dr. Lionel Marks de Chabris is an expert in chronic pain management and addiction medicine. Graduating from McGill University Medical School, Dr. Marks de Charis is board certified in Family Medicine and Emergency Medicine. He is an Ontario based physician with a practice in Pain and Addiction Medicine. He holds diplomas from the American Academy of Pain Management, the Canadian Academy of Pain Management, and the American Board of Addiction Medicine. Dr. Marks de Charis has been a Mentor for the Ontario College of Family Physicians, an Assessor for the College of Physicians and Surgeons of Ontario and is currently an Assistant Professor at the Northern Ontario School of Medicine.

Larry Holbrook, Chief Scientific Officer

Dr. Holbrook, PhD (Neurobiology), has been a senior research scientist in a number of Canadian biotechnology R&D companies for more than 35 years. His main research focus has been the utilization of molecular biology to develop plant made pharmaceuticals, including cannabinoids. He most recently held the position as Chief Scientific Officer at CanniMed.